Advertisement

---

ABBVIE

AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting

[2013-06-17] - Analysis Evaluates Response Rates in Patients with 17p Deletion, Fludarabine-Refractory CLL
Data in Patients with Mantle Cell Lymphoma (MCL) Also Presented


Largest Global Survey of Rheumatoid Arthritis Patients Shows Opportunity for Increased Collaboration Between Doctors And Patients And Further Education About Disease Progression

[2013-06-11] - Multinational, Multidisciplinary Expert Panel Reveals Survey Findings, Asks Patients to Take Pledge as Part of RA: Join the Fight, an AbbVie Global Initiative


Largest Global Survey of Rheumatoid Arthritis Patients Shows Opportunity for Increased Collaboration Between Doctors And Patients And Further Education About Disease Progression

[2013-06-11] -


AbbVie to Participate in 34th Annual Goldman Sachs Global Healthcare Conference

[2013-06-05] -


AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting

[2013-06-03] - Data in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma
Enrollment in Clinical Trials for ABT-199 Continues


AbbVie Announces Market Availability of New CREON® (pancrelipase) 36,000 Lipase-unit Capsules for Patients with Exocrine Pancreatic Insufficiency

[2013-05-30] - Highest Lipase Dose Now Available On the Market


AbbVie to Participate in 2013 Jeffries Global Healthcare Conference

[2013-05-28] -


AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy

[2013-05-20] -


AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy

[2013-05-20] - AbbVie presents results of Phase 2b studies


AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease

[2013-05-17] - First selective JAK1 inhibitor to enter Phase 2 studies in Crohn's disease
Galapagos to fund and complete Phase 2 study; AbbVie to pay Galapagos $50 million upon successful completion, expected in 2015


AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease

[2013-05-14] - AbbVie secures exclusive option to acquire global rights to ALV003
ALV003 has the potential to be the first therapy to treat celiac disease


1 - 2
Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers